Musk's Past PTSD Psychedelics Comments Resurface Amid FDA MDMA Hearing

Comments Elon Musk previously made about the potential of psychedelic substances to help treat post-traumatic stress disorder are drawing renewed attention this week, as the U.S. Food and Drug Administration holds a hearing connected to an MDMA-assisted therapy trial, according to a report from Yahoo Finance.

Musk's Earlier Remarks

The Tesla and SpaceX CEO has spoken in the past about psychedelics as a possible avenue for treating PTSD, a view that has taken on new relevance as U.S. regulators examine emerging clinical evidence on the subject, Yahoo Finance reported. Musk's remarks were not made in connection with any specific company or clinical program, but they have resurfaced as the broader conversation around psychedelic-assisted therapy advances through regulatory channels.

FDA Hearing and Optimi Health's MDMA Trial

The FDA hearing arrives as Optimi Health continues to advance a clinical trial studying MDMA-assisted therapy for PTSD, per the report. The hearing represents another step in an ongoing federal review process for psychedelic-based treatments, an area that has faced a mix of scientific interest and regulatory caution in recent years. Yahoo Finance's report did not detail specific outcomes from the hearing or trial results from Optimi Health's program.

Why It Matters for Tesla Watchers

The story centers on drug policy and mental health treatment rather than Tesla's vehicles, energy business, or stock performance directly. Still, Musk's past public statements continue to attract scrutiny given his outsized profile as one of the most closely watched executives globally, and any commentary he has made on health-related topics tends to circulate widely. Yahoo Finance's report did not indicate any direct involvement by Musk, Tesla, or SpaceX in the FDA hearing or in Optimi Health's ongoing trial.

Source: Yahoo Finance